Phase 3 Ixo-Vec Program Advances
Clinical Scorecard: Phase 3 Ixo-Vec Program Advances
At a Glance
| Category | Detail |
|---|
| Condition | Neovascular Age-Related Macular Degeneration (nAMD) |
| Key Mechanisms | Intravitreal gene therapy using AAV7m8 vector for continuous aflibercept production. |
| Target Population | Treatment-naïve and treatment-experienced patients with nAMD. |
| Care Setting | Clinic-based administration. |
Key Highlights
- Ixo-vec aims to reduce treatment burden with sustained aflibercept expression.
- ARTEMIS and AQUARIUS studies are evaluating the efficacy of a single injection.
- Previous trials showed significant reductions in treatment frequency and stable visual acuity.
- No serious safety concerns reported; mild inflammation manageable with corticosteroids.
- Physician interest in durable therapies for nAMD is high.
Guideline-Based Recommendations
Diagnosis
- Evaluate visual acuity and central subfield thickness in nAMD patients.
Management
- Consider ixo-vec for patients with high treatment burden.
Monitoring & Follow-up
- Monitor visual acuity and CST post-treatment for stability.
Risks
- Monitor for mild to moderate inflammation; no severe adverse events reported.
Patient & Prescribing Data
Patients with high treatment burden from nAMD.
Sustained aflibercept levels observed 4-5 years post-injection.
Clinical Best Practices
- Utilize ixo-vec for patients requiring frequent anti-VEGF injections.
- Implement local corticosteroids for managing inflammation post-treatment.
Related Resources & Content
